Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Paul Turnbull

- PMLiVE

Half of European cancer drug trials ‘biased’, says BMJ

Report says studies exaggerate benefits

- PMLiVE

Four Health and ARK among winners at PM Society Digital Awards

The awards celebrated its 10th year with biggest event yet

- PMLiVE

Democrats’ final pricing plan announced, 250 drugs targeted

Would allow US federal government to negotiate prices of key medicines

- PMLiVE

Insys gets bankruptcy court okay for Subsys sale

Opioid product was focus of racketeering charges

- PMLiVE

Breath test could predict response to immunotherapy

Study found device accurately predicted responses in lung cancer

Report: Customer experience, shaping digital healthcare

In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...

Blue Latitude Health

- PMLiVE

The benefits of uniting in a divergent environment

Thoughts from Emma Statham, chief executive, Four Health

Four Agency Worldwide

- PMLiVE

Encouraging signs in biomarker R&D

The cancer immunotherapy firms ramping-up biomarker R&D

- PMLiVE

J&J puts pressure on rivals with new Erleada okay in prostate cancer

FDA previously granted priority review in this indication

Pharma exhibition stand design with added value

Everyone wants an engaging trade show booth. But, to achieve this, it’s essential to think beyond design and construction.  With over 30 years’ experience in exhibition stand design, we use all...

Apex Events and Exhibitions

- PMLiVE

bluebird bio reveals further encouraging data for CALD gene therapy

Study shows continued benefit in treatment of rare disease

- PMLiVE

Takeda’s HAE drug Takhzyro backed by NICE

New treatment option for rare, hereditary disease

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links